Company Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.
The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Country | United States |
| Founded | 1982 |
| IPO Date | Jan 1, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Amit Kumar Ph.D. |
Contact Details
Address: 3150 Almaden Expressway, Suite 250 San Jose, California 95118 United States | |
| Phone | 408-708-9808 |
| Website | anixa.com |
Stock Details
| Ticker Symbol | ANIX |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0000715446 |
| CUSIP Number | 03528H109 |
| ISIN Number | US03528H1095 |
| Employer ID | 11-2622630 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Amit Kumar Ph.D. | Chief Executive Officer, Chairman and Co-Chair of CBAB |
| Michael J. Catelani CPA, MBA | President, Chief Operating Officer, Chief Financial Officer and Corporate Secretary |
| John Roop | Senior Vice President of Engineering |
| Dr. Pamela D. Garzone Ph.D. | Chief Development Officer and Chair Breast Cancer Clinical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 10-Q | Quarterly Report |
| Feb 8, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 16, 2024 | 10-K | Annual Report |
| Dec 7, 2023 | 8-K | Current Report |
| Sep 6, 2023 | 10-Q | Quarterly Report |
| Jun 14, 2023 | 10-Q | Quarterly Report |
| Apr 17, 2023 | 8-K | Current Report |